Acyclovir Prophylaxis in Stem Cell Transplantation
Acyclovir is administered during stem cell transplant workup and throughout the early post-transplant period to prevent life-threatening herpes simplex virus (HSV) reactivation, which occurs in the majority of HSV-seropositive patients without prophylaxis due to profound immunosuppression from conditioning chemotherapy.
Primary Indication: HSV Reactivation Prevention
The conditioning therapy used before stem cell transplantation causes severe immunosuppression that triggers HSV reactivation in seropositive patients. Acyclovir prophylaxis is the standard of care (AI recommendation) for all HSV IgG-positive patients undergoing stem cell transplantation 1.
Timing and Duration
- Start: Between the beginning of conditioning therapy and day 1 after transplantation 1
- Continue: Until day 30 post-transplant at minimum 1, 2
- Extended duration: For allogeneic transplant recipients, continue for at least 1 year (up to 2 years while on immunosuppressive therapy) 3, 4
- Important caveat: Chemotherapy-induced oral mucositis should be resolved before discontinuing acyclovir 1
Who Needs Prophylaxis
Only HSV-seropositive patients require acyclovir prophylaxis 1. Testing for anti-HSV serostatus is mandatory before transplant (AIII recommendation) 1. HSV-seronegative patients do not need prophylaxis regardless of donor serostatus 1.
Secondary Benefit: VZV Protection
Acyclovir prophylaxis given for HSV also provides protection against varicella-zoster virus (VZV) reactivation 1. This is particularly important because:
- VZV disease is associated with substantial morbidity and mortality in immunosuppressed patients 1
- The standard HSV prophylaxis dose is also effective against VZV during the first 30 days 1
- For allogeneic transplant recipients, VZV prophylaxis should continue for at least 1 year post-transplant 3
Dosing Considerations
While traditional dosing is 1000 mg/day divided into multiple doses, recent evidence supports lower-dose regimens:
- Low-dose option: 400 mg orally twice daily has proven effective and well-tolerated 4, 5
- Ultra-low-dose option: 200 mg/day has shown efficacy for VZV prevention in the middle and late phases 6, 5
The lower doses reduce adverse effects while maintaining efficacy, with one study showing only 4% HSV reactivation rate with 400 mg twice daily over 2 years 4.
Important Clinical Pitfalls
When to Stop Acyclovir
Discontinue acyclovir if CMV prophylaxis or treatment with ganciclovir or foscarnet is initiated, as both drugs are active against HSV 1. This prevents unnecessary polypharmacy and potential drug interactions.
Not for CMV Prevention
Acyclovir is NOT recommended for CMV disease prevention (EI recommendation) 1. It failed to prevent CMV disease after autologous transplantation 1. For CMV, use pre-emptive therapy with ganciclovir or foscarnet based on monitoring 1, 7.
Prolonged Prophylaxis Indications
Extend acyclovir beyond day 30 only for:
- Patients with repeated HSV reactivation episodes after day 30 (BIII recommendation) 1
- Allogeneic transplant recipients (continue for 1 year minimum) 3
- Patients on continued immunosuppressive therapy 3, 4
Monitoring and Safety
Adequate hydration must be maintained to prevent acyclovir-related nephrotoxicity 8. Dosage adjustment is required for patients with renal impairment 8. The drug is generally well-tolerated, with recent studies showing no acyclovir-related adverse events (acute kidney injury, neurotoxicity, or rash) in transplant recipients 4.
Adverse Effects to Monitor
- Renal dysfunction (requires hydration and dose adjustment) 8
- CNS symptoms in patients with renal impairment 8
- Nausea/vomiting (2.7% in clinical trials) 8
- Drug interactions with nephrotoxic agents 8
Algorithm for Acyclovir Use
- Pre-transplant: Check HSV serostatus (mandatory)
- If HSV IgG-positive: Start acyclovir with conditioning therapy
- Continue: Through day 30 minimum (autologous) or 1 year (allogeneic)
- Stop if: Starting ganciclovir/foscarnet for CMV
- Extend if: Repeated HSV reactivation or ongoing immunosuppression
This approach prevents the significant morbidity associated with HSV reactivation, which can cause severe mucositis, esophagitis, and disseminated disease in profoundly immunosuppressed transplant recipients.